Brought to you by 
Cellectis, Pfizer to develop CART therapies for cancer
Jun 2014
Executive Summary
Pfizer Inc. and oncology firm Cellectis SA teamed up to develop chimeric antigen receptor T-cell (CART) cancer immunotherapies aimed at 15 targets selected by the Big Pharma and 12 targets chosen by Cellectis.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
- Includes Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com